COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types.

Benjamin J. Schmiedel^{1,5}, Vivek Chandra^{1,5}, Job Rocha^{1,5}, Cristian Gonzalez-Colin^{1,5}, Sourya Bhattacharyya¹, Ariel Madrigal¹, Christian H. Ottensmeier^{1,4}, Ferhat Ay^{1,2,6}, Pandurangan Vijayanand^{1,3,4,6}.

¹La Jolla Institute for Immunology, La Jolla, CA, USA.

²Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.

³Department of Medicine, University of California San Diego, La Jolla, CA, USA.

⁴Liverpool Head and Neck Centre, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK.

⁵Equally contributed to this work.

⁶Joint senior authors.

Correspondence should be addressed to P.V. (vijay@lji.org).

Key words:

COVID-19, DICE, GWAS, CCR2, IL-10, Immune cells.

ABSTRACT

Common genetic polymorphisms associated with severity of COVID-19 illness can be utilized for discovering molecular pathways and cell types driving disease pathogenesis. Here, we assessed the effects of 679 COVID-19-risk variants on gene expression in a wide-range of immune cell types. Severe COVID-19-risk variants were significantly associated with the expression of 11 protein-coding genes, and overlapped with either target gene promoter or *cis*-regulatory regions that interact with target promoters in the cell types where their effects are most prominent. For example, we identified that the association between variants in the 3p21.31 risk locus and the expression of *CCR2* in classical monocytes is likely mediated through an active *cis*-regulatory region that interacted with *CCR2* promoter specifically in monocytes. The expression of several other genes showed prominent genotype-dependent effects in non-classical monocytes, NK cells, B cells, or specific T cell subtypes, highlighting the potential of COVID-19 genetic risk variants to impact the function of diverse immune cell types and influence severe disease manifestations.

MAIN

The clinical presentation of SARS-CoV-2 infection in humans can range from severe respiratory failure to disease that is very mild or without symptoms¹. Although hyperactivation of various cellular components of the immune system have been observed in patients with severe COVID-19 illness^{2,3}, the host genetic factors that determine susceptibility to severe COVID-19 illness are not well understood. Genome-wide association studies (GWAS) addressing this question have identified a number of genetic variants associated with COVID-19 susceptibility and severity⁴⁻⁷. However, their target genes and the immune cell types where their effects are most prominent are not known. The DICE database of immune cell gene expression, epigenomics and expression quantitative trait loci (eQTLs) (<http://dice-database.org>) was established to precisely answer these questions as well as to help narrow down functional variants in dense haploblocks linked to disease susceptibility^{8,9}. Here, we utilize the DICE database and 3D *cis*-interactome maps to provide a list of target genes and cell types most affected by genetic variants linked to severity of COVID-19 illness.

We systematically assessed the effects of 679 COVID-19-risk variants (defined by the COVID-19 Host Genetics Initiative; release 4 from 20 October 2020⁴; GWAS association P value $< 5 \times 10^{-8}$) on gene expression in 13 different immune cell types and 2 activation conditions (**Supplementary Tables 1 and 2**). The expression of 11 protein-coding genes and 1 non-coding RNA (referred here as eGenes) was associated with the genetic variants linked to severe COVID-19 illness requiring hospitalization (**Fig. 1a** and **Extended data Fig. 1**). Notably, the majority of the eGenes associated with severe COVID-19 illness showed prominent effects in specific immune cell types (**Fig. 1b**). Applying a more liberal GWAS association P value threshold of 1×10^{-5} , we identified 41 additional eGenes that were associated with genetic variants non-significantly linked to severe COVID-19 illness (**Supplementary Table 3**). Some of these variants are likely to reach statistical significance (GWAS association P value $< 5 \times 10^{-8}$) as more donors with severe COVID-19 illness are included in the subsequent analysis phases.

Genetic variants in the 3p21.31 locus have been linked to severity of COVID-19 illness by multiple GWAS studies⁴⁻⁷. These severe COVID-19-risk variants are inherited as a dense >300 kb haploblock that was shown to have entered the human population $>50,000$ years ago from Neanderthals¹⁰. Populations with higher frequency of this Neanderthal-origin COVID-19-risk haplotype have higher risk of severe COVID-19 illness¹⁰. The severe COVID-19-risk variants in the 3p21.31 locus contains 17 known protein-coding genes (**Fig. 2a**), including

SLC6A20, *LZTFL1*, *CCR9*, *FYCO1*, *CXCR6*, *XCR1*, *CCR1*, *CCR3*, *CCR2* and *CCR5*. Among these genes *CCR2* (encoding for C-C type chemokine receptor, also known as monocyte chemoattractant protein 1 receptor) expression showed the strongest association with 3p21.31 severe COVID-19-risk variants identified by GWAS studies⁴ (**Fig. 2a**). Importantly, the risk variants were associated with expression of *CCR2* in certain CD4⁺ memory T cell subsets (T_H17, T_H1/17) and classical monocytes (**Fig. 1a, 2a** and **Supplementary Tables 1** and **2**). Although the *CCR2* promoter did not directly overlap the risk variants, we found that the peak eQTL (rs6808074), located >200kb upstream, directly overlapped an intergenic *cis*-regulatory region that specifically interacted (H3K27ac HiChIP) with *CCR2* promoter in classical monocytes (**Fig. 2b**). These findings suggested that the severe COVID-19-risk variant (rs6808074) likely perturbs the function of a distal enhancer that is important for regulating *CCR2* expression in monocytes. Thus, genetic evidence points to an important role of *CCR2* pathway in the pathogenesis of COVID-19. Patients with severe COVID-19 illness were shown to have increased *CCR2* expression in circulating monocytes as well as very high levels of *CCR2* ligand (*CCL2*) in bronchoalveolar lavage fluid¹¹, supporting the hypothesis that excessive recruitment of *CCR2*-expressing monocytes may drive pathogenic lung inflammation in COVID-19.

Defects in the type 1 interferon pathway have been reported in patients with severe COVID-19 illness¹²⁻¹⁵. We found many severe COVID-19-risk variants in chromosome 21, overlapping the *IFNAR2* gene that encodes for interferon receptor 2, were associated with the expression of *IFNAR2* in multiple immune cell types (**Fig. 3a**). H3K27ac HiChIP-based chromatin interaction maps in this locus showed that the severe COVID-19-risk variants overlapping the *IFNAR2* gene promoter and an intronic enhancer interacted with the promoter of a neighboring gene, *IL10RB* and also influenced its expression levels (**Fig. 3b**). The effects of these risk variants were most prominent in NK cells (rs2284551, adj. association *P* value = 8.99×10^{-7}) (**Fig. 3a**). *IL10RB*, encodes for IL-10 receptor beta, and given the immunomodulatory role of IL-10¹⁶, it is likely that the lower expression on the *IL10RB* in NK cells may perturb their responsiveness to IL-10. Thus, our findings point to a potentially important role for IL-10 signaling and NK cells in influencing susceptibility to severe COVID-19 illness.

The expression of two interferon-inducible genes (*OAS1* and *OAS3*) was also influenced by severe COVID-19-risk variants in chromosome 12. *OAS1* and *OAS3*, encode for oligoadenylate synthase family of proteins that degrades viral RNA and activate antiviral responses¹⁷. *OAS1* showed a peak COVID-19-risk eQTL (rs2057778, adj. association *P* value = 1.77×10^{-7}) specifically in patrolling non-classical monocytes, whereas

OAS3 showed prominent eQTLs in T cells (**Fig. 4a**), further highlighting cell-type-restricted effects of severe COVID-19-risk variants. Interestingly, we found that a severe COVID-19-risk variant (rs2010604, adj. association P value = 4.50×10^{-2}) in the *OAS1/OAS3* locus also influenced the expression of a neighboring gene (*DTX1*) specifically in naïve B cells (**Fig. 4a**). Active chromatin interaction maps in naïve B cells showed that a *cis*-regulatory region near the eQTL (rs2010604) interacts with the promoter of *DTX1*, located >80kb away, and likely modulates its transcriptional activity (**Fig. 4b**). This notion is supported by recent reports showing that promoters can interact with neighboring gene promoters and regulate their expression^{9,18}. *DTX1*, encodes for a ubiquitin ligase Deltex1 that regulates NOTCH activity in B cells¹⁹. Deltex1 has also been shown to promote anergy, a functionally hypo-responsive state, in T cells²⁰; if Deltex1 has a similar functions in B cells, then genetic modulation of *DTX1* levels may have a profound impact on the function of B cells in COVID-19 illness.

Several COVID-19 risk variants located in the promoter region of *TCF19* were associated with its expression in multiple lymphocyte subsets but not in classical or non-classical monocytes (**Fig. 1a**). *TCF19* encodes for a transcription factor TCF19 that has been shown to regulate activation of T cells²¹ and also involved in cell proliferation^{22,23}. A noteworthy example of a highly cell-specific severe COVID-19-risk eGene in regulatory T cells (T_{REG}) was *PDE4A* (**Extended Data Fig. 2**). This gene encodes for phosphodiesterase 4A, which has been shown to reduce the levels of cAMP, and thus influence T cell activity to module immune responses²⁴.

In summary, several severe COVID-19-risk variants show cell-type-restriction of their effects on gene expression, and thus have the potential to impact the function of diverse immune cell types and gene pathways. Our analysis of eQTLs and *cis*-interaction maps in multiple immune cell types enabled a precise definition of the cell types and genes that drive genetic susceptibility to severe COVID-19 illness, potentially contributing to the different clinical outcomes. Our study also highlights how information about common genetic polymorphisms can be used to define molecular pathways and cell types that play a role in disease pathogenesis.

METHODS

The Institutional Review Board (IRB) of the La Jolla Institute for Allergy and Immunology (LJI; IRB protocol no. SGE-121-0714) approved the study. For the DICE study, a total of 91 healthy volunteers were recruited in the San Diego area, who provided leukapheresis samples at the San Diego Blood Bank (SDBB) after written informed consent. Details of gene expression and eQTL analysis in 13 immune cell types and 2 activation conditions have been reported for the DICE project (recalculated to incorporate 4 previously missing RNA-seq samples)⁸, H3K27ac HiChIP data in 5 common immune cell types has been previously reported for the DICE *cis*-interactome project⁹. Genetic variants associated with COVID-19 were downloaded from the COVID-19 Host Genetics Initiative (release 4 from 20 October 2020). Lead genetic variants with GWAS association P value $< 5 \times 10^{-8}$ were utilized for downstream analysis. Linkage disequilibrium (LD) for lead COVID-19-risk-variants was calculated using PLINK v1.90b3w²⁵ for continental ‘super populations’ (AFR, AMR, EAS, EUR, SAS) based on data from the phase 3 of the 1,000 Genomes Project²⁶. SNPs in tight genetic linkage with GWAS lead SNPs (LD threshold $R^2 > 0.8$) in any of the five super-populations were retrieved along with the SNP information (*e.g.*, genomic location, allelic variant, allele frequencies). Utilizing this data set, GWAS SNPs (lead SNPs and SNPs in LD) were analyzed for overlap with eQTLs in the DICE database (raw P value < 0.0001 , adj. association P (FDR) < 0.05 , TPM > 1.0) separately for each cell type to identify COVID-19-risk variants that were associated with gene expression in immune cell types.

DATA AND SOFTWARE AVAILABILITY

The DICE project provides anonymized data for public access at <http://dice-database.org>. Individual-specific RNA-sequencing, genotype, HiChIP and ChIP-seq data are available from the database of Genotypes and Phenotypes (dbGaP Accession number: phs001703.v3.p1).

CODE AVAILABILITY

The code used for the analyses performed in this study is available upon request. The codes used for HiChIP data analysis is available on GitHub at https://github.com/ay-lab/pieQTL_NG.

ACKNOWLEDGMENTS

This work was funded by NIH grants R24-AI108564 (P.V., F.A., C.H.O.), the William K. Bowes Jr Foundation (P.V.), and R35-GM128938 (F.A.).

AUTHOR CONTRIBUTIONS

B.J.S., V.C., C.H.O., F.A., and P.V. conceived the work. B.J.S., V.C., F.A., and P.V. designed the study and wrote the manuscript. J.R., C.G.-C., S.B., and A.M., performed bioinformatic analyses under the supervision of B.J.S., V.C., P.V. and F.A.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

FIGURE LEGENDS

Figure 1. COVID-19-risk variants with eQTL activity in human immune cell types. (a) Genes and cell types influenced by GWAS SNPs linked to severe COVID-19 illness requiring hospitalization. For each cell type (columns), the adj. association P value for the peak GWAS *cis*-eQTL associated with the indicated eGenes (rows) is shown. (b) Fractions of GWAS eGenes linked to severe COVID-19 illness identified in varying numbers of cell types.

Figure 2. Promoter interacting distal *cis*-eQTLs regulate *CCR2* promoter activity specifically in classical monocytes. (a) Genes and cell types most susceptible to the effects of severe COVID-19-risk variants (all with GWAS association P value $< 5 \times 10^{-8}$) in the 3p21.31 locus. The adj. association P value for the peak GWAS *cis*-eQTL associated with the indicated eGenes in each cell type and activation condition is shown (left). Right, mean expression levels (TPM) of *CCR2* gene in classical monocytes (* adj. association P value: 5.94×10^{-3}), from subjects ($n=91$) categorized based on the genotype at the indicated GWAS *cis*-eQTL (each symbol represents an individual subject; adj. association P value calculated by Benjamini-Hochberg method). (b) WashU Epigenome browser tracks for the 3p21.31 locus, severe COVID-19-risk associated GWAS variants (based on GWAS study, see **Extended Data Figure 1a**; red color bars are lead GWAS SNPs, black color bars are SNPs in linkage disequilibrium), adj. association P value for GWAS *cis*-eQTLs associated with expression of *CCR2* expression in classical monocytes (dark red) and naïve B cells (green), recombination rate tracks^{27,28}, H3K27ac ChIP-seq tracks, and H3K27ac HiChIP interactions in classical monocytes and naïve B cells.

Figure 3. COVID-19-risk variants show cell-type-restriction of their effects on gene expression. (a) Mean expression levels (TPM) of selected severe COVID-19-risk associated GWAS eGenes (all with GWAS association P value $< 5 \times 10^{-8}$) in the indicated cell types from subjects ($n=91$) categorized based on the genotype at the indicated peak GWAS *cis*-eQTL; each symbol represents an individual subject, * adj. association P value < 0.05 . (b) WashU Epigenome browser tracks for the *IFNAR2* and *IL10RB* loci, severe COVID-19-risk associated GWAS variants (based on GWAS study, see **Extended Data Figure 1a**; red color bars are lead GWAS SNPs, black color bars are SNPs in linkage disequilibrium), adj. association P value for GWAS *cis*-eQTLs associated

with expression of *IL10RB* in NK cells, recombination rate tracks^{27,28}, H3K27ac ChIP-seq tracks, and H3K27ac HiChIP interactions in NK cells.

Figure 4. Target genes of severe COVID-19-risk variants in chromosome 12. (a) Mean expression levels (TPM) of selected severe COVID-19-risk associated GWAS eGenes (all with GWAS association P value $< 5 \times 10^{-8}$) in the indicated cell types from subjects ($n=91$) categorized based on the genotype at the indicated peak GWAS *cis*-eQTL; each symbol represents an individual subject, * adj. association P value < 0.05 . (b) WashU Epigenome browser tracks for the extended *DTX1* locus, severe COVID-19-risk associated GWAS variants (based on GWAS study, see **Extended Data Figure 1a**; red color bars are lead GWAS SNPs, black color bars are SNPs in linkage disequilibrium), adj. association P value for GWAS *cis*-eQTLs associated with expression of *DTX1* in naïve B cells, recombination rate tracks^{27,28}, H3K27ac ChIP-seq tracks, and H3K27ac HiChIP interactions in naïve B cells.

EXTENDED DATA FIGURE LEGENDS

Extended data Figure 1. Gene and cell types most susceptible to severe COVID-19-risk associated GWAS SNPs. (a) GWAS SNP datasets defined by the COVID-19 Host Genetics Initiative (see **Online Methods**), number of cases and controls in each study (release 4 from 20 October 2020), retrieved GWAS lead SNPs (GWAS association P value $< 5 \times 10^{-8}$) and number of GWAS haploblocks. (b) For each separate GWAS SNP dataset (as defined by the COVID-19 Host Genetics Initiative), the adj. association P value for the peak GWAS *cis*-eQTL associated with the indicated eGenes in each cell type and activation condition is shown.

Extended data Figure 2. Genes and cell types most susceptible to severe COVID-19-risk associated GWAS variants. Mean expression levels (TPM) of *PDE4A*, a severe COVID-19-risk associated GWAS eGene (GWAS association P value $< 5 \times 10^{-8}$), in the indicated cell types from subjects ($n=91$) categorized based on the genotype at the indicated peak GWAS *cis*-eQTL; each symbol represents an individual subject, * adj. association P value < 0.05 .

SUPPLEMENTARY TABLES

Table S1. List of eGenes in each immune cell type and activation condition, along with information on its peak GWAS *cis*-eQTL (GWAS association P value $< 5 \times 10^{-8}$) that is associated with COVID-19 illness.

Table S2. List of eGenes in each immune cell type and activation condition, along with information on all GWAS *cis*-eQTLs (GWAS association P value $< 5 \times 10^{-8}$) that are associated with COVID-19 illness.

Table S3. List of eGenes in each immune cell type and activation condition, along with information on all GWAS *cis*-eQTLs (GWAS association P value $< 1 \times 10^{-5}$) that are associated with COVID-19 illness.

REFERENCES

1. Tay, M.Z., Poh, C.M., Renia, L., MacAry, P.A. & Ng, L.F.P. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol* (2020).
2. Vabret, N. *et al.* Immunology of COVID-19: Current State of the Science. *Immunity* **52**, 910-941 (2020).
3. Meckiff, B.J. *et al.* Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19. *Cell* (2020).
4. Initiative, C.-H.G. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *Eur J Hum Genet* **28**, 715-718 (2020).
5. Severe Covid, G.G. *et al.* Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med* **383**, 1522-1534 (2020).
6. Roberts, G.H.L. *et al.* AncestryDNA COVID-19 Host Genetic Study Identifies Three Novel Loci. *medRxiv*, 2020.10.06.20205864 (2020).
7. Pairo-Castineira, E. *et al.* Genetic mechanisms of critical illness in Covid-19. *medRxiv*, 2020.09.24.20200048 (2020).
8. Schmiedel, B.J. *et al.* Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression. *Cell* **175**, 1701-1715 e16 (2018).
9. Chandra, V. *et al.* Promoter-interacting expression quantitative trait loci are enriched for functional genetic variants. *Nature Genetics* (in press).
10. Zeberg, H. & Paabo, S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. *Nature* (2020).
11. Szabo, P.A. *et al.* Analysis of respiratory and systemic immune responses in COVID-19 reveals mechanisms of disease pathogenesis. *medRxiv*, 2020.10.15.20208041 (2020).
12. Arunachalam, P.S. *et al.* Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. *Science* **369**, 1210-1220 (2020).
13. Bastard, P. *et al.* Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. *Science*, eabd4585 (2020).
14. Hadjadj, J. *et al.* Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* **369**, 718-724 (2020).
15. Zhang, Q. *et al.* Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science*, eabd4570 (2020).
16. Ouyang, W., Rutz, S., Crellin, N.K., Valdez, P.A. & Hymowitz, S.G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. *Annu Rev Immunol* **29**, 71-109 (2011).
17. Sadler, A.J. & Williams, B.R. Interferon-inducible antiviral effectors. *Nat Rev Immunol* **8**, 559-68 (2008).
18. Medina-Rivera, A., Santiago-Algarra, D., Puthier, D. & Spicuglia, S. Widespread Enhancer Activity from Core Promoters. *Trends Biochem Sci* **43**, 452-468 (2018).
19. Izon, D.J. *et al.* Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch1. *Immunity* **16**, 231-43 (2002).
20. Hsiao, H.W. *et al.* Deltex1 is a target of the transcription factor NFAT that promotes T cell anergy. *Immunity* **31**, 72-83 (2009).
21. Best, J.A. *et al.* Transcriptional insights into the CD8(+) T cell response to infection and memory T cell formation. *Nat Immunol* **14**, 404-12 (2013).
22. Zhou, Z.H. *et al.* TCF19 contributes to cell proliferation of non-small cell lung cancer by inhibiting FOXO1. *Cell Biol Int* (2019).
23. Krautkramer, K.A. *et al.* Tcf19 is a novel islet factor necessary for proliferation and survival in the INS-1 beta-cell line. *Am J Physiol Endocrinol Metab* **305**, E600-10 (2013).
24. Wehbi, V.L. & Tasken, K. Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells - Role of Anchored Protein Kinase A Signaling Units. *Front Immunol* **7**, 222 (2016).
25. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**, 559-75 (2007).
26. Genomes Project, C. *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74 (2015).
27. Kong, A. *et al.* A high-resolution recombination map of the human genome. *Nat Genet* **31**, 241-7 (2002).
28. Kong, A. *et al.* Fine-scale recombination rate differences between sexes, populations and individuals. *Nature* **467**, 1099-103 (2010).

Figure 1

Figure 3

Figure 4

Extended Data Figure 1

a

	COVID-19 GWAS phenotype description (https://www.covid19hg.org)	Total cases	Total controls	COVID-19 GWAS lead SNPs	COVID-19 GWAS haploblocks
A1	Very severe respiratory confirmed COVID vs. not hospitalized COVID	269	688	0	0
A2	Very severe respiratory confirmed COVID vs. population	4,933	1,398,672	542	10
B1	Hospitalized COVID vs. not hospitalized COVID	2,430	8,478	14	1
B2	Hospitalized COVID vs. population	8,638	1,736,547	619	9
C1	COVID vs. lab/self-reported negative	24,057	218,062	1	1
C2	COVID vs. population	30,937	1,471,815	195	3
D1	Predicted COVID from self-reported symptoms vs. predicted or self-reported non-COVID	3,024	35,728	1	1

Extended Data Figure 2